|
1. Biologie
|
|
|
NIH to launch genome editing research program [NIH]
|
|
|
|
|
|
Advances
in genome editing made over the past decade now make it possible to
precisely change the DNA code inside living cells. Despite widespread
interest and investment in this field, many challenges remain preventing
broad adoption of this technology in the clinic.
|
|
|
|
|
|
|
|
1.1 Biologie - Gènes
|
|
|
|
2. Etiologie
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
3.1 Prévention - Tabac
|
|
|
Derek Yach: Building a Foundation to accelerate an end to smoking [BMJ Blogs]
|
|
|
|
|
|
The
Foundation’s initial funding source is Philip Morris International
(“PMI”). An enforceable pledge agreement legally binds PMI to provide
the Foundation with US$80 million annually for 12 years, as long as the
Foundation’s independent board of directors certifies annually that it
remains focused on ending smoking and addressing the consequences of
reduced tobacco use on tobacco farmers.
|
|
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
|
Vaping Can Be Addictive and May Lure Teenagers to Smoking, Science Panel Concludes [NY Times]
|
|
|
|
|
|
The
new report by the National Academies of Sciences, Engineering and
Medicine is the most comprehensive analysis of existing research on
e-cigarettes. It concluded the devices are safer than traditional
smoking products and that they do help smokers quit, citing conclusive
proof that switching can reduce smokers’ exposure to deadly tar,
numerous dangerous chemicals and other carcinogens.
|
|
|
|
|
|
|
Public Health Consequences of E-Cigarettes [Nation Academis Press]
|
|
|
|
|
|
Public
Health Consequences of E-Cigarettes reviews and critically assesses the
state of the emerging evidence about e-cigarettes and health. This
report makes recommendations for the improvement of this research and
highlights gaps that are a priority for future research.
|
|
|
|
|
|
|
5.12.10 Immunothérapies - Fusions et acquisitions
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.9 Immunothérapies - SITC
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
FDA to begin releasing clinical study reports in pilot programme [BMJ]
|
|
|
|
|
|
In
Europe, sections of licensing applications, including CSRs, have been
publicly accessible through the European Medicines Agency (EMA) since
2010. To date, the EMA has released millions of pages of CSRs, and since
late 2016 has been making clinical reports publicly available on its
website. Transparency advocates have for years called on the FDA to
follow the EMA’s lead.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.9 Controverses
|
|
|